17282-00-7

Basic information

• Product Name: 2-Amino-3-bromo-5-methylpyridine
• Synonyms: 3-Bromo-5-methyl-2-pyridinamine;TIMTEC-BB SBB000261;AURORA KA-7917;BUTTPARK 33\04-66;2-AMINO-5-METHYL-3-BROMO PYRIDINE;2-AMINO-3-BROMO-5-PICOLINE;2-AMINO-3-BROMO-5-METHYLPYRIDINE;6-AMINO-5-BROMO-3-PICOLINE
• CAS NO: 17282-00-7
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• EINECS: -0
• Product Categories: blocks;Pyridines;Pyridines, Pyrimidines, Purines and Pteredines;Pyridine series;Pyridine;Bromopyridines;Halopyridines;C6Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Amino-pyridine series;Amines;Heterocycles;amine|alkyl bromide
• Mol File: 17282-00-7.mol

Chemical Properties

• Melting Point: 73-76 °C(lit.)
• Boiling Point: 252.348 °C at 760 mmHg
• Flash Point: 106.417 °C
• Appearance: Yellow to beige or brown/Crystalline Powder
• Density: 1.5672 (rough estimate)
• Vapor Pressure: 0.0194mmHg at 25°C
• Refractive Index: 1.5500 (estimate)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.28±0.49(Predicted)
• Water Solubility: Insoluble
• BRN: 471829
• CAS DataBase Reference: 2-Amino-3-bromo-5-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-3-bromo-5-methylpyridine(17282-00-7)
• EPA Substance Registry System: 2-Amino-3-bromo-5-methylpyridine(17282-00-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 17282-00-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-3-bromo-5-methylpyridine is used as a chemical intermediate for the preparation of various imidazo-fused pyridines, pyrazines, pyrimidines, and triazines. These compounds act as JNK and ERK kinase inhibitors, which are important targets for the development of drugs to treat a range of diseases, including cancer and inflammatory disorders.
Additionally, 2-Amino-3-bromo-5-methylpyridine may be used in the synthesis of several other pyridine derivatives, such as:
1. 3-bromo-2-chloro-5-methylpyridine
2. 3-bromo-2-fluoro-5-methylpyridine
3. 8-methyl-1,2,3,5-tetrahydropyrido[3,4-b][1,4]diazepin-4-one
4. 3-bromo-2-(ethylamino)-5-methylpyridine
5. (3-bromo-5-methylpyridin-2-yl)aniline
6. 5-methyl-3-(phenylethynyl)pyridin-2-amine
7. 3-[(2-methoxyphenyl)ethynyl]-5-methylpyridin-2-amine
8. 3-[(4-methoxyphenyl)ethynyl]-5-methylpyridin-2-amine
9. 3-[(3-chlorophenyl)ethynyl]-5-methylpyridin-2-amine
These synthesized compounds can be further utilized in the development of new drugs with specific therapeutic properties, targeting various diseases and medical conditions.

InChI:InChI=1/C6H7BrN2/c1-4-2-5(7)6(8)9-3-4/h2-3H,1H3,(H2,8,9)/p+1

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 

Downstream Products

• 136117-93-6 8-bromo-6-methyl-imidazo<1,2-a>pyridine 
• 155790-02-6 3-Bromo-5-methyl-2-nitro-pyridine 
• 38076-78-7 2-amino-5-methyl-3-pyridine carbonitrile 
• 217090-18-1 5-Methyl-3-(4-methylsulfanyl-phenyl)-pyridin-2-ylamine 
• 221880-25-7 3-<(3-bromo-5-methyl-2-pyridinyl)amino>cyclohex-2-en-1-one 
• 17282-03-0 3-bromo-2-chloro-5-methyl-pyridine 
• 500903-95-7 5-methyl-3-[2-(trimethylsilyl)ethynyl]pyridin-2-ylamine 
• 288254-70-6 5-methyl-3-(phenylethynyl)-2-pyridinylamine 
• 847446-55-3 ethyl 8-bromo-6-methylimidazo[1,2-a]pyridine-2-carboxylate 
• 847446-53-1 8-bromo-6-methyl-2-(4-fluorophenyl)imidazo[1,2-a]pyridine 
• 872492-59-6 N-(3-bromo-5-methylpyridin-2-yl)-N-methylamine 
• 901124-75-2 8-bromo-2-(chloromethyl)-6-methylimidazo[1,2-a]pyridine 
• 20348-17-8 5-methyl-2-amino-3-pyridinol 

Relevant articles and documents

Synthesizing method of (E)-5-methyl-1H-pyrrolo-[2,3-b] pyridine-3-formaldoxime

The invention relates to a synthesizing method of (E)-5-methyl-1H-pyrrolo-[2,3-b] pyridine-3-formaldoxime, which solves the technical problem that an effective synthesizing method is not discovered at present. The synthesizing method provided by the invention comprises the following steps: brominating 2-amino-5-picoline, so as to obtain a compound 1; performing a reaction on the compound 1 and trimethylsilylacetylene under a condition of a Sonogashira coupling reaction, so as to generate a compound 2; performing a reaction on the compound 2 and sodium hydride to form a pyrrole ring, so as to generate a compound 3; performing a reaction on the compound 3 and urotropine, so as to generate a compound 4; performing the compound 4, hydroxylamine hydrochloride and sodium acetate, so as to obtain the target product (E)-5-methyl-1H-pyrrolo-[2,3-b] pyridine-3-formaldoxime. As a sodium acetate, the (E)-5-methyl-1H-pyrrolo-[2,3-b] pyridine-3-formaldoxime is widely applied in the pharmaceutical industry.

Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modelling

A novel series of TGX-221 analogues was prepared and tested for their potency against the p110α, p110β, and p110δ isoforms of the PI3K enzyme, and in two cellular assays. The biological results were interpreted in terms of a p110β comparative model, in order to account for their selectivity towards this isoform. A CH2NH type linker is proposed to allow binding into the specificity pocket proposed to accommodate the high p110β-selectivity of TGX-221, although there was limited steric tolerance for substituents on the pendant ring with the 2-position most favourable for substitution.

Synthesis and study of nucleic acids interactions of novel monomethine cyanine dyes

Six asymmetric monomethine cyanine dyes have been synthesized and their spectral characteristics and interaction with double stranded (ds)DNA have been investigated for their prospective use as fluorescent markers in molecular biology. Therefore, the non-covalent binding of the compounds with dsDNA was explored. Apart from the fluorescence spectroscopy, the study includes UV/Vis spectrophotometry and circular dichroism spectroscopy, as well as the thermal melting experiments. Although the compounds show relatively low binding affinity toward dsDNA and do not have intrinsic fluorescence, in the presence of dsDNA they exhibited considerable enhancement in fluorescence intensity. Therefore the studied dyes show interesting platform for future modifications directed toward more sequence selective derivatives. The compound with the highest affinity toward dsDNA showed interesting anti-proliferative potential and specificity.

Synthesis of 5-bromo-6-methyl imidazopyrazine, 5-bromo and 5-chloro-6-methyl imidazopyridine using electron density surface maps to guide synthetic strategy

Small heteroaromatic rings are valuable monomers in drug discovery that can enable rapid access to novel and desirable chemical space. Installation of a synthetic handle on a heteroaromatic core may be difficult if steric and electronic factors are not in alignment with the desired transformation. Described are practical routes for the construction of 5-bromo-6-methyl imidazopyrazine (1) as well as 5-bromo and 5-chloro-6-methyl imidazopyridines (2a and 2b), which were developed using electron density surface maps encoded with ionization potential to guide synthetic strategy.

ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS

The invention provides compounds of formula (I) pharmaceutically acceptable salt or solvate thereof, in which R1, A1, m and A are as defined in the specification; a process for their preparation; pharmaceutical compositions containin

Substituted pyridines as selective cyclooxygenase-2 inhibitors

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.

2-pyridinyl-3(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors

A series of novel 2-pyridinyl-3-(4-methylsulfonyl)phenylpyridines has been synthesized and evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1, and COX-2. Optimum COX-2 activity is observed by introduction of a substituent at C5 of the central pyridine. 5- Chloro-3-(4-methylsulfonyl)phenyl-2(2-methyl-5-pyridinyl)pyridine 33 was identified as the optimum compound in this series.

Total synthesis of dimethyl sulfomycinamate

The first total synthesis of dimethyl sulfomycinamate (1) is described. Highlights of the synthesis include a selective palladium-catalyzed coupling reaction on the bromotriflate 21, and a condensation reaction to form the oxazole ring.

SYNTHESIS OF THE MUTAGENIC 2-AMINO-1,6-DIMETHYLIMIDAZOPYRIDINE (1,6-DMIP) AND FIVE OF ITS ISOMERS

Synthetic routes to 2-amino-1,6-dimethylimidazopyridine and its 1,5-, 1,7-, 3,5- 3,6- and 3,7-dimethyl isomers from methyl derivatives of 3-hydroxy- or 2-amino-pyridine and 2-chloronicotinic acid are described.

Bromination of Pyridines. II. Bromination of Aminopicolines

The bromination of all ten possible aminopicolines 1-10 was investigated.In general, the major brominated product was that corresponding to electrophilic attack at the sites para or ortho to the amino group.